MX2019001596A - Uso y dosificacion de agentes terapeuticos para endometriosis. - Google Patents
Uso y dosificacion de agentes terapeuticos para endometriosis.Info
- Publication number
- MX2019001596A MX2019001596A MX2019001596A MX2019001596A MX2019001596A MX 2019001596 A MX2019001596 A MX 2019001596A MX 2019001596 A MX2019001596 A MX 2019001596A MX 2019001596 A MX2019001596 A MX 2019001596A MX 2019001596 A MX2019001596 A MX 2019001596A
- Authority
- MX
- Mexico
- Prior art keywords
- endometriosis
- relates
- present
- dosage
- therapeutic agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a agentes farmacéuticos que reducen el riesgo de disminuir la densidad mineral ósea a causa de su efecto reductor de los niveles de estrógeno, y ejercen excelentes efectos terapéuticos sobre la endometriosis. La presente invención se refiere a composiciones farmacéuticas para el tratamiento de la endometriosis, que comprenden el ácido 3-[2-fluoro-5-(2,3-difluoro-6-metoxibenciloxi)-4-metoxifenil]-2,4 -dioxo-1,2,3,4-tetrahidrotieno-[3,4-d]-pirimidin-5-carboxílico o una sal farmacéuticamente aceptable del mismo, los cuales se administran por vía oral una vez al día, a una dosis diaria de entre 50 mg y 75 mg, calculada en forma de base libre.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016155175 | 2016-08-08 | ||
| PCT/JP2017/028504 WO2018030317A1 (ja) | 2016-08-08 | 2017-08-07 | 子宮内膜症治療剤の用法・用量 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019001596A true MX2019001596A (es) | 2019-09-19 |
| MX388825B MX388825B (es) | 2025-03-20 |
Family
ID=61162249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001596A MX388825B (es) | 2016-08-08 | 2017-08-07 | Uso y dosificacion de agentes terapeuticos para endometriosis. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10646491B2 (es) |
| EP (1) | EP3498280B1 (es) |
| JP (1) | JP6987060B2 (es) |
| KR (1) | KR102433001B1 (es) |
| CN (2) | CN109562112A (es) |
| AU (1) | AU2017309015B2 (es) |
| BR (1) | BR112019002513A2 (es) |
| CA (1) | CA3025760A1 (es) |
| EA (1) | EA039240B1 (es) |
| IL (2) | IL292027A (es) |
| MX (1) | MX388825B (es) |
| TW (1) | TWI746613B (es) |
| UA (1) | UA123114C2 (es) |
| WO (1) | WO2018030317A1 (es) |
| ZA (1) | ZA201900777B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3018358T3 (es) * | 2017-06-05 | 2025-05-16 | Kissei Pharmaceutical | Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual |
| SG11201911598WA (en) * | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| EP3873465B1 (en) * | 2018-10-29 | 2025-01-15 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| JP7459086B2 (ja) * | 2018-11-07 | 2024-04-01 | キッセイ薬品工業株式会社 | エストロゲン依存性障害の治療のための組成物及び方法 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| TW202342054A (zh) * | 2022-02-04 | 2023-11-01 | 日商橘生藥品工業股份有限公司 | 經口固形製劑 |
| MA71568A (fr) * | 2022-08-16 | 2025-05-30 | Cms Research & Development Pte. Ltd. | Forme saline et forme cristalline de dérivé de thiénopyrimidinone |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1939204E (pt) * | 2005-10-19 | 2013-03-14 | Kissei Pharmaceutical | Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal |
| KR101631143B1 (ko) * | 2010-02-10 | 2016-06-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 축합 복소환 유도체의 염 및 그 결정 |
-
2017
- 2017-08-07 MX MX2019001596A patent/MX388825B/es unknown
- 2017-08-07 CN CN201780043097.6A patent/CN109562112A/zh active Pending
- 2017-08-07 EP EP17839388.0A patent/EP3498280B1/en active Active
- 2017-08-07 CN CN202310437343.3A patent/CN116270656A/zh active Pending
- 2017-08-07 CA CA3025760A patent/CA3025760A1/en active Pending
- 2017-08-07 UA UAA201901236A patent/UA123114C2/uk unknown
- 2017-08-07 JP JP2018533017A patent/JP6987060B2/ja active Active
- 2017-08-07 US US16/322,227 patent/US10646491B2/en active Active
- 2017-08-07 IL IL292027A patent/IL292027A/en unknown
- 2017-08-07 TW TW106126582A patent/TWI746613B/zh active
- 2017-08-07 AU AU2017309015A patent/AU2017309015B2/en active Active
- 2017-08-07 WO PCT/JP2017/028504 patent/WO2018030317A1/ja not_active Ceased
- 2017-08-07 BR BR112019002513-8A patent/BR112019002513A2/pt not_active Application Discontinuation
- 2017-08-07 EA EA201990249A patent/EA039240B1/ru unknown
- 2017-08-07 KR KR1020197000066A patent/KR102433001B1/ko active Active
-
2019
- 2019-01-30 IL IL264554A patent/IL264554B/en unknown
- 2019-02-06 ZA ZA2019/00777A patent/ZA201900777B/en unknown
-
2020
- 2020-04-08 US US16/843,260 patent/US11382914B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2018030317A1 (ja) | 2019-06-13 |
| AU2017309015B2 (en) | 2022-09-15 |
| US20210046078A1 (en) | 2021-02-18 |
| US11382914B2 (en) | 2022-07-12 |
| IL264554A (en) | 2019-02-28 |
| CN116270656A (zh) | 2023-06-23 |
| IL292027A (en) | 2022-06-01 |
| JP6987060B2 (ja) | 2021-12-22 |
| TW201808297A (zh) | 2018-03-16 |
| UA123114C2 (uk) | 2021-02-17 |
| EP3498280A4 (en) | 2020-03-18 |
| EP3498280B1 (en) | 2024-04-03 |
| CA3025760A1 (en) | 2018-02-15 |
| MX388825B (es) | 2025-03-20 |
| EP3498280A1 (en) | 2019-06-19 |
| US10646491B2 (en) | 2020-05-12 |
| TWI746613B (zh) | 2021-11-21 |
| ZA201900777B (en) | 2020-08-26 |
| IL264554B (en) | 2022-05-01 |
| BR112019002513A2 (pt) | 2019-05-14 |
| EA201990249A1 (ru) | 2019-07-31 |
| WO2018030317A1 (ja) | 2018-02-15 |
| KR20190037225A (ko) | 2019-04-05 |
| EA039240B1 (ru) | 2021-12-22 |
| CN109562112A (zh) | 2019-04-02 |
| KR102433001B1 (ko) | 2022-08-18 |
| AU2017309015A1 (en) | 2019-02-14 |
| US20190175600A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001596A (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| MX2019002265A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| ECSP13012423A (es) | FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NEUROPATICO | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| BR112015019264A8 (pt) | cápsulas para o tratamento de helicobacter pylori e seu uso". | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| BR112015025058A2 (pt) | composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma | |
| CO2019003808A2 (es) | Composición farmacéutica que comprende antagonista receptor de mineralocorticoides y uso de la misma | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| UY37412A (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| BRPI0412523A (pt) | forma de dosagem oral de mesilato de saquinavir | |
| WO2020032883A3 (en) | Synergistic effects of a novel ketoprofen formulation including a gastro protective agent | |
| UY37798A (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil | |
| ES2468665B1 (es) | Composición farmacéutica de sulfato de condroitina y celecoxib | |
| TR201008460A1 (tr) | Eslikarbazepinin saşe formülasyonları. | |
| AR076016A1 (es) | Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria |